12 Stocks Moving In Tuesday's Pre-Market Session

Gainers

LDR Holding Corp LDRH rose 62.31 percent to $36.65 in pre-market trading as the company agreed to be acquired by Zimmer Biomet Holdings Inc ZBH for $37 per share.

Sarepta Therapeutics Inc SRPT shares rose 31.46 percent to $21.10 in pre-market trading as the company disclosed that the FDA has requested dystrophin data prior to making a decision on eteplirsen NDA.

CTI BioPharma Corp CTIC shares rose 12.53 percent to $0.484 in pre-market trading as the company presented long-term follow up data for pacritinib at the ASCO.

United Natural Foods, Inc. UNFI rose 10.74 percent to $43.00 in pre-market trading as the company reported better-than-expected earnings for its third quarter and raised its 2016 fiscal year outlook.

Regulus Therapeutics Inc RGLS shares rose 7.58 percent to $6.39 in pre-market trading after the company revealed positive top-line results from the primary endpoint analysis of one of its ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

ITT Educational Services, Inc. ESI shares fell 39.09 percent to $1.34 in pre-market trading apparently driven by a MarketWatch article assuring the company “is facing increased scrutiny from regulators amid questions from its accreditor about whether it can meet its standards.”

DryShips Inc. DRYS shares fell 34.32 percent to $1.55 in pre-market trading after the company announced that it has breached some financial covenants. The company also said that it has yet to make final balloon installments on three matured banking facilities and three lenders have declared event a default.

Vascular Biogenics Ltd VBLT shares fell 13.87 percent to $5.90 in pre-market trading after surging 72.54 percent on Monday. The company reported a $24 million registered direct offering.

Helios and Matheson Analytics Inc HMNY shares fell 14.70 percent to $6.15 in pre-market trading after jumping 548.26 percent on Monday.

Valeant Pharmaceuticals Intl Inc VRX shares 10.54 percent to $25.80 in pre-market trading after the company reported weaker-than-expected earnings for the first quarter and reduced its full year adjusted earnings outlook.

Biogen Inc BIIB fell 9.58 percent to $262.00 in pre-market trading as the company’s Phase 2 SYNERGY study of opicinumab missed the primary and secondary endpoint.

Alexion Pharmaceuticals, Inc. ALXN shares fell 9.16 percent to $140.80 following the release of disappointing data for the company’s Phase 3 clinical trial data of Soliris (eculizumab) for the treatment of refractory generalized myasthenia gravis (gMG). Soliris failed to achieve its primary endpoint, even though several secondary objectives were conquered..